Metastatic Prostate Cancer Prognosis Calculator

What This Calculator Estimates

This tool provides a prognostic estimate for metastatic prostate cancer based on established clinical factors. It uses patient age, Gleason score, PSA level at diagnosis, the specific sites of metastasis, and performance status to generate a survival probability estimate. The calculation is derived from validated prognostic models used in clinical oncology to help contextualize disease trajectory.

How Prognosis Is Estimated

The calculator applies a statistical model that weights each clinical factor according to its known impact on survival outcomes. The model accounts for the following relationships:

• Age – Older age at diagnosis is associated with a modest reduction in estimated survival, independent of other factors.
• Gleason score – Higher scores (8–10) indicate more aggressive tumor biology and are linked to shorter prognosis.
• PSA at diagnosis – Very high PSA levels (above 100 ng/mL) correlate with greater tumor burden and worse outcomes.
• Metastasis site – Visceral metastases (liver, lung) carry a worse prognosis than bone-only or lymph node involvement.
• ECOG performance status – Reduced functional status (score 2 or higher) significantly shortens expected survival.

The model assumes standard systemic therapy (androgen deprivation therapy with or without chemotherapy or novel hormonal agents). It does not account for individual treatment responses, clinical trial participation, or emerging therapies.

How to Use the Calculator

1. Enter the patient's age at diagnosis.
2. Select the Gleason score from the available range (6 to 10).
3. Enter the PSA level at diagnosis in ng/mL.
4. Select the primary site of metastasis (bone, lymph node, visceral, or multiple).
5. Choose the ECOG performance status (0 to 4).
6. Click Calculate to generate the estimated prognosis.

All fields are required for a valid estimate. The tool will not produce a result if any input is missing.

Understanding the Results

The output displays an estimated median survival in months and a 1-year survival probability percentage. These figures represent population-level estimates derived from clinical data, not a precise prediction for any individual patient.

Median survival is the time at which half of patients with similar characteristics would be expected to survive. 1-year survival probability is the estimated percentage of patients who would survive at least 12 months from diagnosis.

These estimates are most reliable when all input factors are accurately recorded. Small changes in Gleason score or performance status can produce meaningful shifts in the output, reflecting their strong prognostic weight.

Common Mistakes to Avoid

• Using PSA from after treatment initiation – PSA levels change rapidly once therapy begins. Always use the value at initial diagnosis.
• Selecting the wrong ECOG score – ECOG 0 means fully active; ECOG 1 means restricted in strenuous activity but ambulatory. Overestimating performance status leads to overly optimistic estimates.
• Misclassifying metastasis site – If multiple sites are involved, select "multiple." Selecting only one site when visceral involvement exists will underestimate disease severity.
• Ignoring the confidence interval – The estimate is a median. Individual outcomes vary widely. Use the result as a guide, not a definitive timeline.

Limitations of This Estimate

This calculator is based on historical cohort data and may not reflect outcomes for patients receiving modern combination therapies (e.g., androgen receptor pathway inhibitors, PARP inhibitors, or immunotherapy). It does not account for:

• Prior local treatment (surgery or radiation)
• Genomic alterations (e.g., BRCA, AR-V7)
• Number of prior lines of therapy
• Comorbidities that affect treatment tolerance
• Response to specific treatments

The tool is intended for educational and informational purposes only. It is not a substitute for clinical judgment or a formal oncology consultation.

Practical Use Cases

• Patient education – Helping patients understand how their specific clinical factors relate to published outcomes.
• Treatment planning discussions – Providing a framework for conversations about treatment intensity and goals of care.
• Clinical research context – Comparing a patient's profile to trial eligibility criteria or published survival data.
• Medical education – Demonstrating how multiple prognostic factors combine to influence survival estimates.